Evaluation of the efficacy of Thymus kotschyanus extract as an additive treatment in patients with ulcerative colitis: a randomized double-blind placebo-controlled trial.
Calprotectin
Inflammation
Lamiaceae
SCCAI
Thymus kotschyanus
UC patients
Ulcerative colitis
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
28
12
2021
accepted:
05
04
2022
pubmed:
21
6
2022
medline:
30
11
2022
entrez:
20
6
2022
Statut:
ppublish
Résumé
Ulcerative colitis (UC) is one of the chronic diseases which is increasing in prevalence and patients suffer from illness flare-ups. UC standard regimen treatment has various side effects besides the efficacy, so there is an interest in administering complementary medicine to reduce adverse effects and increase the efficacy, as well. The aim of this study was to evaluate the efficacy and anti-inflammatory effect of Thymus kotschyanus as an additive treatment in a randomized double-blind placebo-controlled trial of UC patients. Thirty UC out-patients with mesalazine regimen treatment that fulfilled the inclusion criteria were participated in a 12 week trial and were randomly chosen for the treatment and control group. Fifteen patients were administered a placebo as a control and 15 patients were received Thymus kotschyanus extract by a dose of 0.5 g in a day in the treatment group. Laboratory tests were performed at baseline and week 12. The primary outcome was a reduction in fecal calprotectin as the main intestine inflammatory marker. Likewise, reduction in SCCAI, SIDBQ, and SEO indices were considered as secondary aims. Fecal calprotectin was decreased by 54.74% in the treatment group, as compared with the placebo group at week 12 (p = 0.02). A significant reduction in SCCAI was also shown between the two study groups (p = 0.01). Thymus kotschyanus extract was safe and no severe side effects were reported. Administration of Thymus kotschyanus revealed improvement in UC symptoms by the intestinal anti-inflammation effect of the plant and could be suggested as a potential additive treatment in UC patients. The study protocol has been registered under the identification code: IRCT20200406046965N2.
Sections du résumé
BACKGROUND
BACKGROUND
Ulcerative colitis (UC) is one of the chronic diseases which is increasing in prevalence and patients suffer from illness flare-ups. UC standard regimen treatment has various side effects besides the efficacy, so there is an interest in administering complementary medicine to reduce adverse effects and increase the efficacy, as well. The aim of this study was to evaluate the efficacy and anti-inflammatory effect of Thymus kotschyanus as an additive treatment in a randomized double-blind placebo-controlled trial of UC patients.
METHODS
METHODS
Thirty UC out-patients with mesalazine regimen treatment that fulfilled the inclusion criteria were participated in a 12 week trial and were randomly chosen for the treatment and control group. Fifteen patients were administered a placebo as a control and 15 patients were received Thymus kotschyanus extract by a dose of 0.5 g in a day in the treatment group. Laboratory tests were performed at baseline and week 12. The primary outcome was a reduction in fecal calprotectin as the main intestine inflammatory marker. Likewise, reduction in SCCAI, SIDBQ, and SEO indices were considered as secondary aims.
RESULTS
RESULTS
Fecal calprotectin was decreased by 54.74% in the treatment group, as compared with the placebo group at week 12 (p = 0.02). A significant reduction in SCCAI was also shown between the two study groups (p = 0.01). Thymus kotschyanus extract was safe and no severe side effects were reported.
CONCLUSION
CONCLUSIONS
Administration of Thymus kotschyanus revealed improvement in UC symptoms by the intestinal anti-inflammation effect of the plant and could be suggested as a potential additive treatment in UC patients. The study protocol has been registered under the identification code: IRCT20200406046965N2.
Identifiants
pubmed: 35723850
doi: 10.1007/s10787-022-00991-3
pii: 10.1007/s10787-022-00991-3
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
Mesalamine
4Q81I59GXC
Plant Extracts
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2145-2152Subventions
Organisme : Mashhad University of Medical Sciences
ID : 980801
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y et al (2015) Promising biological therapies for ulcerative colitis: a review of the literature. World J Gastrointest Pathophysiol 6(4):219–227
doi: 10.4291/wjgp.v6.i4.219
pubmed: 26600980
pmcid: 4644886
Algieri F, Rodriguez-Nogales A, Garrido-Mesa N, Zorrilla P, Burkard N, Pischel I et al (2014) Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. J Crohns Colitis 8(8):775–788
doi: 10.1016/j.crohns.2013.12.012
pubmed: 24411672
Almanea A, Abd El-Aziz GS, Ahmed MMMJB (2019) The potential gastrointestinal health benefits of Thymus vulgaris essential oil: a review. Biomed Pharmacol 12(04):1793–1799
doi: 10.13005/bpj/1810
Bakhtiarian A, Aarabi Moghaddam F, Zamani MM, Ghamami SG, Farahanikia B, Khanavi M (2011) Anti-inflammatory effect of Thymus kotschyanus Boiss. & Hohen. Extract on rat’s hind paw edema induced by Carrageenan. JMPIR 10(37):25–32
Basch E, Ulbricht C, Hammerness P, Bevins A, Sollars D (2004) Thyme (Thymus vulgaris L.) Thymol. J Herbal Pharmacother 4:49–67
doi: 10.1080/J157v04n01_07
Bukovská A, Cikoš Š, Juhás Š, Il’ková G, Rehák P, Koppel J (2007) Effects of a combination of thyme and oregano essential oils on TNBS-induced colitis in mice. Mediat Inflam 2007:023296
doi: 10.1155/2007/23296
Chamanara M, Abdollahi A, Rezayat SM, Ghazi-Khansari M, Dehpour A, Nassireslami E et al (2019) Thymol reduces acetic acid-induced inflammatory response through inhibition of NF-kB signaling pathway in rat colon tissue. Inflammopharmacology 27(6):1275–1283
doi: 10.1007/s10787-019-00583-8
pubmed: 30903350
Costa MF, Durço AO, Rabelo TK, Barreto RSS, Guimarães AG (2019) Effects of carvacrol, thymol and essential oils containing such monoterpenes on wound healing: a systematic review. J Pharm Pharmacol 71(2):141–155
doi: 10.1111/jphp.13054
pubmed: 30537169
Ghasemi G, Alirezalu A, Ghosta Y, Jarrahi A, Safavi SA, Abbas-Mohammadi M et al (2020) Composition, antifungal, phytotoxic, and insecticidal activities of Thymus kotschyanus essential oil. Molecules 25(5):1152
doi: 10.3390/molecules25051152
pubmed: 32143475
pmcid: 7179150
Gholijani N, Amirghofran Z (2016) Effects of thymol and carvacrol on T-helper cell subset cytokines and their main transcription factors in ovalbumin-immunized mice. J Immunotoxicol 13(5):729–737
doi: 10.3109/1547691X.2016.1173134
pubmed: 27413998
Guslandi M (1998) Nitric oxide and inflammatory bowel diseases. Eur J Clin Invest 28(11):904–907
doi: 10.1046/j.1365-2362.1998.00377.x
pubmed: 9824433
Hassanzadeh M, Emami S, Asili J, Tayarani-Najaran Z (2011) Review of the essential oil composition of Iranian Lamiaceae. J Essent Oil Res 23:35–74
doi: 10.1080/10412905.2011.9700429
Jahani R, Mojab F, Mahboubi A, Nasiri A, Tahamtani A, Faizi M (2019) An in-vivo study on anticonvulsant, anxiolytic, and sedative-hypnotic effects of the polyphenol-rich thymus kotschyanus extract; evidence for the involvement of GABA(A) receptors. Iran J Pharm Res 18(3):1456–1465
pubmed: 32641954
pmcid: 6934950
Khanavi M, Farahanikia B, Rafiee F, Dalili D, Safaripour E, Ajani Y et al (2011) Reversal of resistance in MRSA strains by Thymus kotschyanus essential oil. J Essent Oil Bear Plants 14(6):684–692
doi: 10.1080/0972060X.2011.10643990
Li M-C, He S-H (2004) IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 10(5):620–625
doi: 10.3748/wjg.v10.i5.620
pubmed: 14991925
pmcid: 4716896
Liu T, Zhang L, Joo D, Sun SC (2017) NF-κB signaling in inflammation. Sig Transduct Target Ther 2:17023
doi: 10.1038/sigtrans.2017.23
Liu D-M, Zhou C-Y, Meng X-L, Wang P, Li W (2018) Thymol exerts anti-inflammatory effect in dextran sulfate sodium-induced experimental murine colitis. Trop J Pharm Res 17:1803
doi: 10.4314/tjpr.v17i9.18
Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V et al (2018) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164
doi: 10.1093/ecco-jcc/jjy113
Madsen K (2002) Combining T cells and IL-10: a new therapy for Crohn’s disease? Gastroenterology 123(6):2140–2144
doi: 10.1053/gast.2002.37289
pubmed: 12454869
Morteza-Semnani K, Rostami B, Akbarzadeh M (2006) Essential oil composition of Thymus kotschyanus and Thymus pubescens from Iran. J Essent Oil Res 18(3):272–274
doi: 10.1080/10412905.2006.9699085
Navaei MS, Taleb A, Isfahani M, Amin G, Faghihi A, Lakeh MM (2012) Study on the phytochemical constituents of Thymus kotschyanus Boiss. Et Hohen and its efficacy on the symptoms’ improvement of irritant bowel syndrome. Res Pharm Sci 7(5):741
Pathirana WGW, Chubb SP, Gillett MJ, Vasikaran SD (2018) Faecal calprotectin. The clinical biochemist. Reviews 39(3):77–90
Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho J-K (2008) Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14(27):4280–4288
doi: 10.3748/wjg.14.4280
pubmed: 18666314
pmcid: 2731177
Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ et al (1999) Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54(4):386–390
doi: 10.1034/j.1399-0039.1999.540408.x
pubmed: 10551422
Tahmasebi P, Abtahi Froushani SM, Afzale AN (2019) Thymol has beneficial effects on the experimental model of ulcerative colitis. Avicenna J Phytomed 9(6):538–550
pubmed: 31763213
pmcid: 6823534
Tohidi B, Rahimmalek M, Arzani A (2018) Variations in chemical composition and bioactive compounds of Thymus kotschyanus Boiss & Hohen populations originated from different collection sites. J Essent Oil Bear Plants 21(5):1272–1283
doi: 10.1080/0972060X.2018.1533435
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF (2017) Ulcerative colitis. Lancet (london, England) 389(10080):1756–1770
doi: 10.1016/S0140-6736(16)32126-2
pubmed: 27914657